DOP2012000044A - Anticuerpos contra el extodominio de erbb3 y usos de los mismos - Google Patents

Anticuerpos contra el extodominio de erbb3 y usos de los mismos

Info

Publication number
DOP2012000044A
DOP2012000044A DO2012000044A DO2012000044A DOP2012000044A DO P2012000044 A DOP2012000044 A DO P2012000044A DO 2012000044 A DO2012000044 A DO 2012000044A DO 2012000044 A DO2012000044 A DO 2012000044A DO P2012000044 A DOP2012000044 A DO P2012000044A
Authority
DO
Dominican Republic
Prior art keywords
erbb3
same
antibodies
receiver
antigen
Prior art date
Application number
DO2012000044A
Other languages
English (en)
Spanish (es)
Inventor
Birgit Schoeberl
Ulrik Nielsen
Michael Feldhaus
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000044(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of DOP2012000044A publication Critical patent/DOP2012000044A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DO2012000044A 2009-08-21 2012-02-20 Anticuerpos contra el extodominio de erbb3 y usos de los mismos DOP2012000044A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21

Publications (1)

Publication Number Publication Date
DOP2012000044A true DOP2012000044A (es) 2012-06-30

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000044A DOP2012000044A (es) 2009-08-21 2012-02-20 Anticuerpos contra el extodominio de erbb3 y usos de los mismos

Country Status (21)

Country Link
EP (1) EP2467164A2 (ko)
JP (1) JP5752687B2 (ko)
KR (1) KR20120059568A (ko)
CN (1) CN103002912A (ko)
AU (1) AU2010284018C1 (ko)
BR (1) BR112012003809A2 (ko)
CA (1) CA2771744A1 (ko)
CR (1) CR20120108A (ko)
DO (1) DOP2012000044A (ko)
EA (1) EA201200195A1 (ko)
EC (1) ECSP12011740A (ko)
IL (1) IL218097A0 (ko)
IN (1) IN2012DN01518A (ko)
MA (1) MA33582B1 (ko)
MX (1) MX336091B (ko)
NI (1) NI201200027A (ko)
PE (1) PE20121585A1 (ko)
SG (1) SG178509A1 (ko)
TN (1) TN2012000057A1 (ko)
WO (1) WO2011022727A2 (ko)
ZA (1) ZA201201195B (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2129396B1 (en) 2007-02-16 2013-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
DK3351558T3 (da) * 2009-11-13 2020-06-02 Daiichi Sankyo Europe Gmbh Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme
EP2516469B1 (en) 2009-12-22 2016-03-30 Roche Glycart AG ANTI-HER3 Antibodies and uses thereof
CN102858335B (zh) 2010-03-11 2015-04-15 梅里麦克制药股份有限公司 Erbb3抑制剂在三阴性乳腺癌和基底样乳腺癌治疗中的用途
BR112012025730B1 (pt) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
KR102027011B1 (ko) 2010-08-20 2019-09-30 노파르티스 아게 표피 성장 인자 수용체 3 (ｈｅｒ3)에 대한 항체
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IT1402149B1 (it) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
JP6033783B2 (ja) * 2010-11-01 2016-11-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐａｎ−ｈｅｒ抗体組成物
US8476409B2 (en) 2011-04-19 2013-07-02 Merrimack Pharmaceuticals, Inc. Bispecific anti-IGF-1R and anti-ErbB3 antibodies
JPWO2012176779A1 (ja) * 2011-06-20 2015-02-23 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
IN2014CN03042A (ko) 2011-09-30 2015-07-03 Regeneron Pharma
AU2012318541B2 (en) 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
EP2788377B1 (en) * 2011-11-09 2019-01-23 The UAB Research Foundation Her3 antibodies and uses thereof
EP3590538A1 (en) 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
WO2013124297A1 (en) * 2012-02-22 2013-08-29 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US20160232293A1 (en) * 2013-10-17 2016-08-11 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
NZ724013A (en) * 2014-02-28 2019-11-29 Merus Nv Antibodies that bind egfr and erbb3
CN110642952B (zh) * 2014-08-14 2021-05-25 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017069628A2 (en) 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
EP3665200A4 (en) 2017-08-09 2021-04-28 University of Saskatchewan HER3 LIAISON AGENTS AND RELATED USES
BR112020002695A2 (pt) 2017-08-09 2020-08-25 Merus N.V. anticorpos que se ligam à egfr e cmet
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
JP2021534811A (ja) * 2018-06-22 2021-12-16 シーアールディー ファーマシューティカルズ インコーポレイティド 抗ｈｅｒ３抗体およびその用途
AU2021360625A1 (en) * 2020-10-14 2023-06-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof
WO2023198138A1 (zh) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 抗体或其抗原结合片段及其医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2129396B1 (en) * 2007-02-16 2013-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof

Also Published As

Publication number Publication date
AU2010284018C1 (en) 2015-10-15
CR20120108A (es) 2012-06-05
KR20120059568A (ko) 2012-06-08
TN2012000057A1 (en) 2013-09-19
ECSP12011740A (es) 2013-02-28
CA2771744A1 (en) 2011-02-24
AU2010284018A1 (en) 2012-03-22
ZA201201195B (en) 2015-07-29
JP2013506622A (ja) 2013-02-28
MX336091B (es) 2016-01-08
PE20121585A1 (es) 2012-11-29
SG178509A1 (en) 2012-04-27
IN2012DN01518A (ko) 2015-06-05
AU2010284018B2 (en) 2014-06-05
CN103002912A (zh) 2013-03-27
EA201200195A1 (ru) 2012-12-28
WO2011022727A3 (en) 2013-06-27
IL218097A0 (en) 2012-04-30
EP2467164A2 (en) 2012-06-27
WO2011022727A2 (en) 2011-02-24
MX2012002172A (es) 2012-05-29
MA33582B1 (fr) 2012-09-01
BR112012003809A2 (pt) 2019-09-24
NI201200027A (es) 2013-01-29
JP5752687B2 (ja) 2015-07-22

Similar Documents

Publication Publication Date Title
DOP2012000044A (es) Anticuerpos contra el extodominio de erbb3 y usos de los mismos
CY1118761T1 (el) Αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης 3 (her3)
CL2018002380A1 (es) Divisional de la solicitud 2433-2012 por anticuerpos reactivos con b7-h3, fragmentos inmunológicamente activos de los mismos y sus usos.
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
ECSP099637A (es) Anticuerpos contra el erbb3 y los usos de los mismos
CL2016002547A1 (es) Anticuerpos contra her2 biespecíficos
EA201491573A1 (ru) Применение передающего сигнал домена cd2 в химерных антигенспецифических рецепторах второго поколения
BR112018009129A2 (pt) receptores de antígeno quimérico que visam her2
BR112018014986A2 (pt) composição farmacêutica compreendendo construtos de anticorpo biespecífico
DOP2015000269A (es) Composiciones y métodos para alterar la señalización del segundo mensajero
UY34813A (es) Proteínas de unión a antígeno dirigidas contra el receptor st2
UY37005A (es) Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos
MX2017003596A (es) Celulas t de receptor de antigeno quimerico co-estimulador que toman como diana a il13r-alfa-2.
CR20150493A (es) Composiciones de amri contra el componente c5 del complemento y métodos para su uso
CR20140479A (es) Moduladores del receptor del estrogeno y sus usos
CL2017002641A1 (es) Construcciones de anticuerpos biespecíficos contra cdh3 y cd3
UY37026A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
UY34601A (es) ?mezclas fungicidas de pirazol?.
CY1119154T1 (el) Anti-vla-4 αντισωματα
CO2019009787A2 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
TR201911084T4 (tr) İnsan yapımı camlı fiberler.
TR201905272T4 (tr) İmmünojenik bileşim.
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
MX2018004289A (es) Receptores de antigenos quimericos dirigidos a psca.
CL2017001445A1 (es) Fibras de polipropileno mejoradas, métodos para producirlas y sus usos para la producción de productos de fibrocemento.